Diagnosis and treatment of pulmonary hypertension: European guidelines 2009;Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009

Pneumologie

Volumn 64, Issue 7, 2010, Pages 401-414

  Hoeper, M M ^a   Ghofrani, H A ^b   Gorenflo, M ^c   Grunig E ^d   Schranz, D ^b   Rosenkranz, S ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Abteilung Pneumologie   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM ANTAGONIST; CONTRACEPTIVE AGENT; CYCLOSPORIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; FLUCONAZOLE; GLIBENCLAMIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; KETOCONAZOLE; NICORANDIL; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; RIFAMPICIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN;

DISEASE CLASSIFICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG EMBOLISM; LUNG TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VEIN OBSTRUCTION; REVIEW;

COOPERATIVE BEHAVIOR; CROSS-CULTURAL COMPARISON; DIAGNOSIS, DIFFERENTIAL; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PROGNOSIS;

EID: 77954886357     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1244112     Document Type: Review

References (69)

1. Olschewski H, Hoeper M M., Borst M M. et al. Diagnosis and therapy of chronic pulmonary hypertension. Pneumologie 2006 60 749-771
2. Olschewski H, Hoeper M M., Borst M M. et al. Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol 2007 96 301-330
3. Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 25 2243-2278
4. Galie N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009 34 1219-1263
5. Galie N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 30 2493-2537
6. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009 34 888-894
7. Badesch D B., Champion H C., Sanchez M A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54 55-66
8. Rich S, Dantzker D R., Ayres S M. et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987 107 216-223 (Pubitemid 17137857)
9. Tongers J, Schwerdtfeger B, Klein G et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007 153 127-132
10. Hoeper M M., Pletz M W., Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007 29 944-950
11. Fisher M R., Forfia P R., Chamera E et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009 179 615-621
12. Arcasoy S M., Christie J D., Ferrari V A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003 167 735-740
13. Fisher M R., Criner G J., Fishman A P. et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007 30 914-921
14. Tunariu N, Gibbs S J., Win Z et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007 48 680-684
15. Resten A, Maitre S, Humbert M et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004 183 65-70
16. Reichelt A, Hoeper M M., Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol 2009 71 49-54
17. Hoeper M M., Lee S H., Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006 48 2546-2552
18. Jing Z C., Jiang X, Han Z Y. et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009 33 1354-1360
19. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 111 3105-3111
20. Galie N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009 30 394-403
21. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006 114 1482-1489
22. de Man F S., Handoko M L., Groepenhoff H et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009 34 669-675
23. Dupuis J, Hoeper M M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008 31 407-414
24. Wilkins M R., Wharton J, Grimminger F, Ghofrani H A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008 32 198-209
25. Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008 31 801-901
26. Barst R J., Rubin L J., Long W A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 334 296-302
27. Barst R J., Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 169 441-447
28. Barst R J., Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006 47 2049-2056
29. Galie N, Brundage B H., Ghofrani H A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 119 2894-2903
30. Galie N, Olschewski H, Oudiz R J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 117 3010-3019
31. Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008 371 2093-2100
32. Galie N, Beghetti M, Gatzoulis M A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006 114 48-54
33. Galie N, Ghofrani H A., Torbicki A et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005 353 2148-2157 (Pubitemid 41653106)
34. Rubin L J., Badesch D B., Barst R J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 346 896-903
35. Channick R N., Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 358 1119-1123 (Pubitemid 32971843)
36. Simonneau G, Rubin L J., Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008 149 521-530
37. Simonneau G, Barst R J., Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 165 800-804
38. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 347 322-329 (Pubitemid 34815354)
39. Oudiz R J., Galie N, Olschewski H et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54 1971-1981
40. Hoeper M M., Gall H, Seyfarth H J. et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009 34 132-137
41. McLaughlin V V., Oudiz R J., Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 174 1257-1263
42. Hoeper M M., Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005 26 858-863
43. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 62 1088-1093
44. Bull T M., Fagan K A., Badesch D B. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005 31 451-464, vi
45. Hoeper M M., Seyfarth H J., Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007 30 1096-1102
46. Reichenberger F, Voswinckel R, Steveling E et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006 28 563-567
47. Grannas G, Neipp M, Hoeper M M. et al. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation 2008 85 524-531
48. Sitbon O, Lascoux-Combe C, Delfraissy J F. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008 177 108-113
49. Grigioni F, Potena L, Galie N et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006 25 1241-1246
50. Califf R M., Adams K F., McKenna W J. et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997 134 44-54
51. Packer M, McMurray J, Massie B M. et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005 11 12-20
52. Alaeddini J, Uber P A., Park M H. et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004 94 1475-1477
53. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi M D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007 50 2136-2144
54. Lewis G D., Shah R, Shahzad K et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007 116 1555-1562
55. Lewis G D., Lachmann J, Camuso J et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007 115 59-66
56. Behr J, Ryu J H. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008 31 1357-1367
57. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008 32 1371-1385
58. Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008 32 619-628
59. Chaouat A, Bugnet A S., Kadaoui N et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 172 189-194 (Pubitemid 40981192)
60. Thabut G, Dauriat G, Stern J B. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005 127 1531-1536
61. Hoeper M M., Mayer E, Simonneau G, Rubin L J. Chronic Thromboembolic Pulmonary Hypertension. Circulation 2006 113 2011-2020
62. Jais X, D'Armini A M., Jansa P et al. Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial. J Am Coll Cardiol 2008 52 2127-2134
63. Hughes R J., Jais X, Bonderman D et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006 28 138-143 (Pubitemid 44914271)
64. Hughes R, George P, Parameshwar J et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 2005 60 707
65. Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005 128 2599-2603 (Pubitemid 41507615)
66. Hoeper M M., Kramm T, Wilkens H et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005 128 2363-2367
67. Ghofrani H A., Schermuly R T., Rose F et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003 167 1139-1141 (Pubitemid 36459662)
68. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007 30 922-927
69. Bresser P, Fedullo P F., Auger W R. et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004 23 595-600